At a glance
- Originator Novartis
- Class Antiprotozoals; Guanidines
- Mechanism of Action Adenosylmethionine decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Malaria
- Discontinued Pneumocystis pneumonia
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 30 Jul 1998 No-Development-Reported for Cancer in Switzerland (Unknown route)
- 30 Jul 1998 No-Development-Reported for Malaria in Israel (Unknown route)